Hub : Traits :

Medication: Allopurinol

145 significantly associated models · 45 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 2 26592429 28607344 12 2 7.5e-18 3.6e-24 9.1e-01 100 AC074117.10 PPM1G
2 4 9370814 11156010 4 10 2.8e-56 4.2e-69 NaN NaN RP11-448G15.3 SLC2A9 WDR1
3 4 87655053 90061475 5 8 5.8e-48 5.7e-174 4.7e-86 51 ABCG2 NUDT9 PKD2 PPM1K
4 6 25266147 26689223 2 1 1.0e-10 1.1e-12 2.3e-03 82 U91328.21
5 7 72674074 73738067 1 1 3.3e-08 1.9e-08 1.0e+00 100 MLXIPL
6 10 60712592 62185494 1 1 2.5e-07 6.2e-09 7.3e-03 79 SLC16A9
7 11 63305184 66262606 6 7 7.0e-11 2.4e-15 NaN NaN ARL2 CAPN1 NRXN2 OVOL1 SNX15 VEGFB
8 12 57249600 58677299 1 1 6.6e-09 3.1e-11 1.2e-03 76 KIF5A
9 12 121659684 123326374 2 2 3.0e-09 9.7e-10 1.1e-01 93 MLXIP WDR66
10 15 75444033 76878362 1 1 4.5e-09 6.2e-07 2.1e-01 94 UBE2Q2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Crohns Disease (2017) 1.52 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Irritable Bowel Disease (IBD) 1.17 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Breast Cancer 1.88 1 1 3.0 0.00 1.0e+00 PPM1K
Body Mass Index (BMI) (2010) 1.67 1 0 0.0 0.00 1.0e+00 MLXIP
Fasting Glucose 2.59 2 2 6.1 0.00 1.0e+00 AC074117.10 PPM1G
HDL Cholesterol 1.87 2 2 6.1 0.00 1.0e+00 KIF5A MLXIPL
LDL Cholesterol 1.11 1 0 0.0 0.00 1.0e+00 OVOL1
Triglycerides 16.46 4 4 12.1 -0.96 3.8e-02 AC074117.10 KIF5A MLXIPL PPM1G
Blood Eosinophil Count 0.90 4 2 6.1 -0.83 1.7e-01 CAPN1 MLXIPL OVOL1 SNX15
Blood Platelet Count 2.39 10 7 21.2 -0.52 1.0e-01 AC074117.10 CAPN1 KIF5A MLXIP MLXIPL NUDT9 OVOL1 PPM1G SLC2A9 UBE2Q2
Blood Red Count 1.00 5 2 6.1 -0.35 5.0e-01 KIF5A MLXIP RP11-448G15.3 SNX15 UBE2Q2
Blood White Count 2.20 6 3 9.1 -0.84 3.8e-02 AC074117.10 KIF5A MLXIPL PPM1G RP11-448G15.3 SLC16A9
Heel T-Score 1.75 7 3 9.1 -0.59 9.4e-02 ABCG2 CAPN1 OVOL1 PKD2 PPM1K SLC16A9 UBE2Q2
BMI 1.60 7 3 9.1 0.68 4.6e-02 CAPN1 KIF5A MLXIP MLXIPL NRXN2 PPM1K SLC2A9
Height 1.43 11 9 27.3 0.63 2.9e-02 AC074117.10 ARL2 CAPN1 MLXIP MLXIPL NUDT9 OVOL1 PPM1G SLC16A9 SLC2A9 WDR66
Waist Hip Ratio (WHR) 0.98 2 1 3.0 0.00 1.0e+00 MLXIP MLXIPL
Systolic Blood Pressure 1.32 6 0 0.0 -0.98 5.0e-04 AC074117.10 MLXIP OVOL1 PPM1G SLC16A9 WDR66
Smoking Status 1.11 1 1 3.0 0.00 1.0e+00 NRXN2
Allergy or Eczema 1.72 4 1 3.0 -0.43 5.7e-01 AC074117.10 MLXIP OVOL1 PPM1G
Cardiovascular Disease 1.89 6 2 6.1 -0.99 5.0e-05 AC074117.10 MLXIPL OVOL1 PPM1G SNX15 WDR66
Hypothyroidism (self reported) 1.52 1 0 0.0 0.00 1.0e+00 MLXIP
Respiratory disease 1.00 1 1 3.0 0.00 1.0e+00 KIF5A
Type 2 Diabetes (T2D) 2.00 2 2 6.1 0.00 1.0e+00 AC074117.10 PPM1G
Lung FEV1/FVC ratio 0.60 2 0 0.0 0.00 1.0e+00 PPM1K SLC2A9
Lung FVC 0.84 1 0 0.0 0.00 1.0e+00 RP11-448G15.3
Hair Pigment 0.25 5 3 9.1 -0.36 5.5e-01 AC074117.10 KIF5A MLXIPL OVOL1 PPM1G
Tanning 0.33 3 1 3.0 0.00 1.0e+00 AC074117.10 MLXIPL PPM1G
Number of treatments/medications taken 1.92 3 0 0.0 0.00 1.0e+00 AC074117.10 OVOL1 PPM1G
Sensitivity / hurt feelings 0.90 1 0 0.0 0.00 1.0e+00 U91328.21
Relative age of first facial hair 1.49 3 0 0.0 0.00 1.0e+00 AC074117.10 ARL2 OVOL1
Ever used hormone-replacement therapy (HRT) 1.75 1 0 0.0 0.00 1.0e+00 PPM1G
Medication: Metformin 1.21 1 0 0.0 0.00 1.0e+00 AC074117.10
Impedance of leg (right) 1.08 6 1 3.0 0.70 1.2e-01 AC074117.10 MLXIP MLXIPL PPM1K SLC2A9 WDR66
Leg fat-free mass (left) 1.90 8 4 12.1 -0.96 1.7e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Trunk fat percentage 0.74 2 1 3.0 0.00 1.0e+00 MLXIP NRXN2
Heel bone mineral density (BMD) T-score, automated (left) 1.46 3 0 0.0 0.00 1.0e+00 OVOL1 PKD2 PPM1K
High blood pressure 1.53 2 1 3.0 0.00 1.0e+00 OVOL1 WDR66
Hayfever, allergic rhinitis or eczema 1.94 4 1 3.0 0.95 5.3e-02 AC074117.10 OVOL1 PPM1G U91328.21
Sitting height 1.87 8 7 21.2 -0.96 1.9e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
High blood pressure (mother) 1.73 1 0 0.0 0.00 1.0e+00 WDR66
Body mass index (BMI) 1.28 4 1 3.0 -0.99 1.5e-02 CAPN1 MLXIP MLXIPL NRXN2
Impedance of leg (left) 1.16 6 2 6.1 0.70 1.3e-01 AC074117.10 MLXIP MLXIPL PPM1K SLC2A9 WDR66
Leg predicted mass (left) 1.90 8 4 12.1 -0.96 1.6e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Trunk fat mass 1.13 3 1 3.0 -0.98 2.5e-02 MLXIP NRXN2 WDR66
Waist circumference 1.21 2 1 3.0 0.00 1.0e+00 MLXIP PPM1K
Past tobacco smoking 1.13 1 0 0.0 0.00 1.0e+00 NRXN2
Had menopause 4.22 2 2 6.1 0.00 1.0e+00 AC074117.10 PPM1G
Forced vital capacity (FVC) 1.04 4 0 0.0 0.55 4.5e-01 CAPN1 PPM1K SLC16A9 WDR66
Heel bone mineral density (BMD) T-score, automated (right) 1.41 3 0 0.0 0.00 1.0e+00 OVOL1 PKD2 PPM1K
Heart attack 1.17 1 0 0.0 0.00 1.0e+00 KIF5A
Allergy 1.54 2 2 6.1 0.00 1.0e+00 KIF5A OVOL1
Diabetes (self-reported) 2.04 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Medication: Simvastatin 1.56 1 0 0.0 0.00 1.0e+00 AC074117.10
Weight 1.76 7 3 9.1 -0.96 4.4e-04 AC074117.10 MLXIP MLXIPL NRXN2 PPM1G U91328.21 WDR66
Impedance of arm (right) 1.52 3 2 6.1 0.00 1.0e+00 AC074117.10 MLXIPL SLC2A9
Arm fat percentage (right) 0.90 2 1 3.0 0.00 1.0e+00 MLXIP NRXN2
Trunk fat-free mass 2.20 8 7 21.2 -0.98 9.9e-06 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Hip circumference 1.91 4 3 9.1 -0.97 4.9e-03 MLXIP MLXIPL NRXN2 WDR66
Alcohol intake versus 10 years previously 2.13 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Forced expiratory volume in 1-second (FEV1) 0.98 2 0 0.0 0.00 1.0e+00 CAPN1 PPM1K
Pulse rate 1.13 1 0 0.0 0.00 1.0e+00 AC074117.10
Asthma 1.18 2 1 3.0 0.00 1.0e+00 KIF5A U91328.21
Medication: Cholesterol lowering 1.84 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Forced expiratory volume in 1-second (FEV1), Best measure 0.87 2 0 0.0 0.00 1.0e+00 CAPN1 U91328.21
Impedance of arm (left) 1.58 3 2 6.1 0.00 1.0e+00 AC074117.10 MLXIPL SLC2A9
Arm fat mass (right) 1.26 3 1 3.0 -0.98 2.1e-02 MLXIP NRXN2 WDR66
Trunk predicted mass 2.22 8 7 21.2 -0.98 1.1e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Standing height 1.59 10 7 21.2 -0.69 2.6e-02 AC074117.10 ARL2 CAPN1 MLXIP NUDT9 PPM1G SLC16A9 SLC2A9 U91328.21 WDR66
Birth weight of first child 1.95 1 0 0.0 0.00 1.0e+00 WDR66
Headache pain in last month 1.33 1 0 0.0 0.00 1.0e+00 NUDT9
Medication for cholesterol, blood pressure or diabetes 1.23 1 0 0.0 0.00 1.0e+00 AC074117.10
Gout (self-reported) 60.62 22 21 63.6 1.00 3.1e-38 ABCG2 AC074117.10 ARL2 CAPN1 KIF5A MLXIP MLXIPL NRXN2 NUDT9 OVOL1 PKD2 PPM1G PPM1K RP11-448G15.3 SLC16A9 SLC2A9 SNX15 U91328.21 UBE2Q2 VEGFB WDR1 WDR66
Medication: Amlodipine 1.71 1 0 0.0 0.00 1.0e+00 OVOL1
Forced vital capacity (FVC), Best measure 1.08 3 0 0.0 0.00 1.0e+00 CAPN1 SLC16A9 WDR66
Body fat percentage 0.81 2 1 3.0 0.00 1.0e+00 MLXIP NRXN2
Leg fat percentage (right) 1.08 3 1 3.0 -1.00 2.7e-03 CAPN1 MLXIP NRXN2
Arm fat-free mass (right) 2.27 8 6 18.2 -0.97 4.6e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Comparative body size at age 10 1.35 4 0 0.0 -0.48 5.2e-01 AC074117.10 CAPN1 MLXIP OVOL1
Qualifications: College or University degree 0.52 1 0 0.0 0.00 1.0e+00 MLXIP
Medication for pain relief, constipation, heartburn 1.55 1 0 0.0 0.00 1.0e+00 PPM1G
Medication: Blood pressure 1.32 1 0 0.0 0.00 1.0e+00 WDR66
Whole body fat mass 1.21 2 1 3.0 0.00 1.0e+00 MLXIP NRXN2
Leg fat mass (right) 1.39 3 1 3.0 0.00 1.0e+00 MLXIP NRXN2 PPM1K
Arm predicted mass (right) 2.21 8 6 18.2 -0.97 5.1e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Pulse rate, automated reading 1.66 3 2 6.1 0.00 1.0e+00 AC074117.10 MLXIPL PPM1G
Alcohol intake frequency. 2.80 4 2 6.1 0.97 3.3e-02 AC074117.10 MLXIPL PPM1G UBE2Q2
Comparative height size at age 10 1.42 8 3 9.1 -0.82 1.2e-02 AC074117.10 CAPN1 MLXIP PPM1G SLC16A9 SLC2A9 U91328.21 WDR66
Hypertension (Self-reported) 1.56 2 1 3.0 0.00 1.0e+00 OVOL1 WDR66
Forced expiratory volume in 1-second (FEV1), predicted 0.86 1 0 0.0 0.00 1.0e+00 SLC16A9
Whole body fat-free mass 2.12 8 7 21.2 -0.98 3.2e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Leg fat-free mass (right) 1.83 8 4 12.1 -0.96 1.6e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Arm fat percentage (left) 0.97 2 1 3.0 0.00 1.0e+00 MLXIP NRXN2
Long-standing illness, disability or infirmity 0.85 1 0 0.0 0.00 1.0e+00 U91328.21
Diabetes diagnosed by doctor 1.91 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Medication for cholesterol 1.52 1 0 0.0 0.00 1.0e+00 AC074117.10
Back pain experienced in last month 1.66 2 0 0.0 0.00 1.0e+00 NUDT9 WDR66
Mineral and other dietary supplements 1.72 1 0 0.0 0.00 1.0e+00 KIF5A
Asthma (self-reported) 1.18 1 1 3.0 0.00 1.0e+00 KIF5A
Osteoporosis (self-reported) 1.74 1 0 0.0 0.00 1.0e+00 PKD2
Osteoarthritis (self-reported) 1.75 1 0 0.0 0.00 1.0e+00 U91328.21
Whole body water mass 2.14 8 7 21.2 -0.98 3.2e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Leg predicted mass (right) 1.83 8 4 12.1 -0.96 1.5e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Arm fat mass (left) 1.27 2 1 3.0 0.00 1.0e+00 MLXIP NRXN2
Number of self-reported non-cancer illnesses 1.92 1 0 0.0 0.00 1.0e+00 AC074117.10
Medication: Blood pressure 1.88 1 1 3.0 0.00 1.0e+00 OVOL1
Pain type(s) experienced in last month: Hip pain 2.12 1 0 0.0 0.00 1.0e+00 MLXIP
Supplements: Fish oil (including cod liver oil) 2.06 1 0 0.0 0.00 1.0e+00 KIF5A
High cholesterol (Self-reported) 3.75 2 2 6.1 0.00 1.0e+00 AC074117.10 PPM1G
Medication: Bendroflumethiazide 1.29 2 0 0.0 0.00 1.0e+00 NUDT9 WDR66
Medication: Lisinopril 1.42 1 0 0.0 0.00 1.0e+00 MLXIP
Medication: Atorvastatin 2.77 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Ever smoked 1.84 1 0 0.0 0.00 1.0e+00 NRXN2
Basal metabolic rate 2.04 8 5 15.2 -0.97 6.8e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Leg fat percentage (left) 0.98 2 0 0.0 0.00 1.0e+00 MLXIP NRXN2
Arm fat-free mass (left) 2.11 8 6 18.2 -0.97 4.2e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66
Diastolic blood pressure, automated reading 0.83 1 0 0.0 0.00 1.0e+00 OVOL1
Vascular/heart problems diagnosed by doctor 1.50 3 1 3.0 0.00 1.0e+00 MLXIP OVOL1 WDR66
Cholesterol lowering medication 1.94 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Heart attack/myocardial infarction (self-reported) 1.18 1 0 0.0 0.00 1.0e+00 KIF5A
Impedance of whole body 1.42 5 2 6.1 0.62 2.7e-01 AC074117.10 MLXIPL PPM1K SLC2A9 WDR66
Leg fat mass (left) 1.35 3 1 3.0 0.00 1.0e+00 MLXIP NRXN2 PPM1K
Arm predicted mass (left) 2.18 8 6 18.2 -0.98 3.8e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WDR66

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 7 0.2005 1.40
GTEx Adipose Visceral Omentum 7 0.3438 1.56
GTEx Adrenal Gland 3 0.2059 1.42
GTEx Artery Aorta 4 0.1344 1.34
GTEx Artery Coronary 2 0.1691 1.37
GTEx Artery Tibial 8 0.2127 1.39
GTEx Brain Caudate basal ganglia 0 0.0000 1.25
GTEx Brain Cerebellar Hemisphere 1 0.0672 1.36
GTEx Brain Cerebellum 1 0.0505 1.33
GTEx Brain Cortex 1 0.0966 1.27
GTEx Brain Frontal Cortex BA9 0 0.0000 1.31
GTEx Brain Hippocampus 0 0.0000 1.24
GTEx Brain Hypothalamus 0 0.0000 1.28
GTEx Brain Nucleus accumbens basal ganglia 0 0.0000 1.29
GTEx Brain Putamen basal ganglia 0 0.0000 1.32
GTEx Breast Mammary Tissue 2 0.1013 1.40
GTEx Breast Mammary Tissue (Male) 1 0.0838 1.26
GTEx Breast Mammary Tissue (Female) 0 0.0000 1.35
GTEx Cells EBV-transformed lymphocytes 1 0.0703 1.33
GTEx Cells Transformed fibroblasts 6 0.1429 1.30
GTEx Colon Sigmoid 3 0.2052 1.46
GTEx Colon Transverse 4 0.1938 1.42
GTEx Esophagus Gastroesophageal Junction 1 0.0692 1.30
GTEx Esophagus Mucosa 4 0.1205 1.34
GTEx Esophagus Muscularis 6 0.1856 1.40
GTEx Heart Atrial Appendage 1 0.0633 1.23
GTEx Heart Left Ventricle 0 0.0000 1.33
GTEx Liver 1 0.1395 1.40
GTEx Lung 2 0.0696 1.32
GTEx Muscle Skeletal 5 0.1730 1.34
GTEx Nerve Tibial 9 0.2083 1.37
GTEx Ovary 2 0.2203 1.42
GTEx Pancreas 3 0.1838 1.36
GTEx Pituitary 1 0.0897 1.33
GTEx Prostate 0 0.0000 1.40
GTEx Skin Not Sun Exposed Suprapubic 4 0.1627 1.34
GTEx Skin Sun Exposed Lower leg 5 0.1374 1.33
GTEx Small Intestine Terminal Ileum 1 0.2169 1.48
GTEx Spleen 1 0.0709 1.39
GTEx Stomach 0 0.0000 1.33
GTEx Testis 4 0.1268 1.37
GTEx Thyroid 6 0.1500 1.38
GTEx Uterus 0 0.0000 1.34
GTEx Vagina 1 0.1575 1.32
GTEx Whole Blood 4 0.2007 1.39
METSIM Adipose 7 0.1518 1.31
NTR Blood 1 0.0416 1.30
ROSMAP Brain Pre-frontal Cortex 8 0.1822 1.35
YFS Blood 2 0.0433 1.27
CommonMind Brain Pre-frontal Cortex 6 0.1116 1.30
TCGA Breast Tumor 1 0.1304 1.60
TCGA Breast Normal 5 0.1188 1.24
TCGA Ovarian Tumor 0 0.0000 1.15
TCGA Prostate Tumor 3 0.0867 1.32